The Association for Frontotemporal Degeneration (AFTD) has shared that two drugs have been selected for evaluation in a new platform trial aimed at accelerating the development of treatments for progressive supranuclear palsy (PSP).

548 participants responded to the FTD Disorders Registry’s April Quick Question on accessing respite care.

576 people answered the FTD Disorders Registry’s March Quick Question where we asked about what types of FTD-related research content respondents would find most valuable. The information will be used to help develop new content for our Registry dashboard, website, and printed materials.

629 people answered the FTD Disorders Registry’s February Quick Question asking how often they feel socially isolated due to their or their loved one’s symptoms from a frontotemporal degeneration (FTD) disorder.